GlassScriptPhysician profile
Fnu Salman
NPI 1003479155
$901.43
in general payments reported to CMS, 2019-2025
14 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $30.16 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $157.66 | 2025 | |
| Amgen INC. | $115.20 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $110.24 | 2025 | |
| Atricure, INC. | $109.49 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Actelion Pharmaceuticals US, INC. | $99.16 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $97.03 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $46.29 | 2025 | |
| Abbott Laboratories | $30.56 | 2025 | Perclose Prostyle |
| Kiniksa Pharmaceuticals International, Plc | $30.16 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $23.11 | 2025 | |
| Pfizer INC. | $22.36 | 2025 | |
| Philips North America LLC | $21.77 | 2025 | Ecc Solutions |
| E.R. Squibb & Sons, L.L.C. | $20.55 | 2025 | Eliquis |
| Chiesi USA, INC. | $17.85 | 2025 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.